Evolus, Inc. $EOLS Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. increased its position in Evolus, Inc. (NASDAQ:EOLS) by 121.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 598,145 shares of the company’s stock after buying an additional 327,926 shares during the period. Assenagon Asset Management S.A.’s holdings in Evolus were worth $2,458,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in Evolus by 2.0% during the second quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock worth $784,000 after acquiring an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after purchasing an additional 1,838 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Evolus by 7.5% in the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock valued at $316,000 after purchasing an additional 2,383 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after purchasing an additional 2,837 shares during the period. Finally, Quantbot Technologies LP grew its holdings in shares of Evolus by 10.0% during the 3rd quarter. Quantbot Technologies LP now owns 32,692 shares of the company’s stock worth $201,000 after purchasing an additional 2,961 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Stock Performance

EOLS stock opened at $6.94 on Wednesday. Evolus, Inc. has a 1 year low of $3.86 and a 1 year high of $10.20. The firm has a market cap of $457.07 million, a P/E ratio of -10.36 and a beta of 1.34. The stock has a 50-day simple moving average of $6.32 and a 200-day simple moving average of $5.55.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $73.14 million during the quarter, compared to analysts’ expectations of $72.52 million. During the same quarter in the previous year, the business earned ($0.30) earnings per share. On average, equities research analysts predict that Evolus, Inc. will post -0.38 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on EOLS. BTIG Research restated a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, Wall Street Zen downgraded shares of Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.